Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Tamara Ghanem

- PMLiVE

Lucid Group Lucky Lunches prove a spellbinding hit this summer

Lucid Group Lucky Lunches have been running throughout the summer months, giving our teams the chance to network and connect outside of the office - as well as enjoying a...

Lucid Group Communications Limited

bear in mirror

Money, money, money

Could it be, that money isn't everything afterall? Surely not.

Page & Page Health

- PMLiVE

Amgen reveals more data on KRAS drug

Unveiled an overall disease control rate of 100%

- PMLiVE

Novo follows Sanofi, Lilly with insulin price cut in US

Price cut will be effective from January 2020

- PMLiVE

Sumitomo Dainippon goes big on biotech with $3bn Roivant deal

Could acquire up to 11 Roivant spinouts

- PMLiVE

GSK eyes follow-up HPV vaccine

Announces new alliance with Chinese pharma Innovax

How to dramatically increase ROI on your eDetailing content

Take your e-detailing content and make it available to HCPs 24/7 – without losing the ‘guided’ experience that makes it so valuable.

Anthill Agency

The changing face of pharma in the precision era

Blue Latitude Health speaks to Nancy Brandt, a Senior Leader in Global Medical Information at a top 20 biopharma organisation. Here, she reveals what pharmaceutical companies need to do to...

Blue Latitude Health

Creative problem solving, solved

Customer Experience Consultant Eimear Power explains how pharma teams can unlock their creativity and foster truly innovative ideas.

Blue Latitude Health

- PMLiVE

Lucid’s Summer Fridays Shone

Lucid Group has been enjoying long weekends throughout the summer thanks to Summer Fridays, a concept introduced in line with Lucid’s agile working policy.Employees have been encouraged to spread their...

Lucid Group Communications Limited

- PMLiVE

Novartis’ lung cancer drug wins FDA Breakthrough Therapy Designation

Provides hope for new treatment of rare cancer

Roche Basel Switzerland

Roche scores EU approval twice for Tecentriq in lung cancer

Carves out space in a market dominated by MSD's Keytruda

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links